TP53 P47S

CI-VAR-00003352Explore in graph →NP_000537.3:p.Pro47SerNM_000546.5:c.139C>TClinVar 43588 CIViC 504 rs1800371

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
TP53 P47S	Cisplatin	Predictive	E	Supports Resistance	2	accepted	EID1209 The P47S (rs1800371) variant of TP53 is observed in 1.5% in African Americans and between 6% and 8% in certain African populations but has not been detected in Caucasian Americans. This paper reports … (full text at CIViC) PMID 27034505 · Jennis et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
43588	Benign	reviewed by expert panel	3	Hereditary cancer-predisposing syndrome; Li-Fraumeni syndrome 1; Li-Fraumeni syndrome; Malignant tumor of breast; Hereditary breast ovarian cancer syndrome; Breast and/or ovarian cancer; Cervical cancer	germline/somatic	27	Aug 05, 2024	clinvar